A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas

Inclusion Criteria: * Histologically diagnosed recurrent anaplastic astrocytoma or recurrent glioblastoma multiforme * At least 18 years of age * Performance status of 0 and 1 on the Eastern Cooperative Oncology Group (ECOG) criteria * One or more measurable disease * Adequate hematologic (neutrophil count \>= 1500/uL, platelets \>= 100,000/uL), hepatic (transaminase =\< upper normal limit (UNL)x2.5, bilirubin level =\< UNLx1.5, alkaline phosphatase =\< UNLx2.5), and renal (creatinine clearance \>= 30mL/min) * Expected life time more than at least 2 months * A patients who signed the informed consent prior to the participation in the study Exclusion Criteria: * A pregnant or lactating patient * A patient of childbearing potential without being tested for pregnancy at baseline or with a positive test. (A premenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential.) * A man or woman of childbearing potential without the willingness to use a contraceptive measures during the study * A patient with history of another malignant disease within past 3 years, except curatively treated basal cell carcinoma of the skin, cervical carcinoma in situ, and early gastric cancer * Medically uncontrolled serious heart, lung, neurological, psychological, or metabolic disease * Uncontrolled serious infection * Enrollment in other study within 30 days * Hemorrhage on baseline radiologic examination * A patient who refused to sign the informed consent